Shandong Buchang Pharmaceuticals (603858.SH) has spent 528 million yuan to repurchase 3.03% of its shares.
BuXiang Pharmaceuticals (603858.SH) announced that as of September 18, 2024, the company has completed the central competitive bidding...
Shandong Buchang Pharmaceuticals (603858.SH) announced that as of September 18, 2024, the company has repurchased a total of 33.5555 million shares through centralized bidding trading. The repurchased shares account for 3.03% of the company's total share capital. The highest purchase price was 17.44 yuan per share and the lowest purchase price was 14.16 yuan per share. The total amount paid for the repurchases so far is 528 million yuan (excluding transaction fees).
Related Articles
Q TECH (01478) intends to sell 51% stake of its Indian subsidiary to Dixon, India for a total consideration of 5.53 billion Rupees.
JL Mag Rare-Earth (06680) announces profit growth expectation in the first half of the year, with a net profit attributable to shareholders of 3 billion to 3.35 billion yuan, a year-on-year increase of 151%-180%.
ACESO LIFE SCI (00474) is selling a total of 569 million shares of Huatian International Construction Investment.
Q TECH (01478) intends to sell 51% stake of its Indian subsidiary to Dixon, India for a total consideration of 5.53 billion Rupees.
JL Mag Rare-Earth (06680) announces profit growth expectation in the first half of the year, with a net profit attributable to shareholders of 3 billion to 3.35 billion yuan, a year-on-year increase of 151%-180%.
ACESO LIFE SCI (00474) is selling a total of 569 million shares of Huatian International Construction Investment.
RECOMMEND
Jensen Huang Confirms NVIDIA to Begin H20 Chip Shipments to China
15/07/2025
Manus Exits China Market Amid $500 Million Valuation, Prompting Concerns Over AI Agent Sector Outlook
15/07/2025
Trump to Allocate $70 Billion in AI and Energy Investment, Escalating the Race for Technological Dominance
15/07/2025
